vs
Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and DYNAVAX TECHNOLOGIES CORP (DVAX). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $75.1M, roughly 1.3× SAUL CENTERS, INC.). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 8.7%, a 19.7% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 10.6%). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 6.2%).
Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
BFS vs DVAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $94.9M |
| Net Profit | $6.5M | $26.9M |
| Gross Margin | — | — |
| Operating Margin | 65.4% | 22.4% |
| Net Margin | 8.7% | 28.4% |
| Revenue YoY | 10.6% | 17.7% |
| Net Profit YoY | -19.6% | 53.0% |
| EPS (diluted) | $0.15 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | — | ||
| Q3 25 | $72.0M | $94.9M | ||
| Q2 25 | $70.8M | $95.4M | ||
| Q1 25 | $71.9M | $68.2M | ||
| Q4 24 | $67.9M | $72.0M | ||
| Q3 24 | $67.3M | $80.6M | ||
| Q2 24 | $66.9M | $73.8M | ||
| Q1 24 | $66.7M | $50.8M |
| Q4 25 | $6.5M | — | ||
| Q3 25 | $10.5M | $26.9M | ||
| Q2 25 | $10.7M | $18.7M | ||
| Q1 25 | $9.8M | $-96.1M | ||
| Q4 24 | $8.1M | $7.0M | ||
| Q3 24 | $14.5M | $17.6M | ||
| Q2 24 | $14.4M | $11.4M | ||
| Q1 24 | $13.6M | $-8.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 73.6% | — | ||
| Q2 24 | 74.2% | — | ||
| Q1 24 | 72.8% | — |
| Q4 25 | 65.4% | — | ||
| Q3 25 | 69.1% | 22.4% | ||
| Q2 25 | 68.7% | 15.1% | ||
| Q1 25 | 66.5% | -34.7% | ||
| Q4 24 | 82.9% | -2.3% | ||
| Q3 24 | 72.8% | 12.5% | ||
| Q2 24 | 75.0% | 7.0% | ||
| Q1 24 | 72.4% | -35.0% |
| Q4 25 | 8.7% | — | ||
| Q3 25 | 14.6% | 28.4% | ||
| Q2 25 | 15.1% | 19.6% | ||
| Q1 25 | 13.6% | -141.0% | ||
| Q4 24 | 11.9% | 9.8% | ||
| Q3 24 | 21.5% | 21.8% | ||
| Q2 24 | 21.6% | 15.4% | ||
| Q1 24 | 20.4% | -17.2% |
| Q4 25 | $0.15 | — | ||
| Q3 25 | $0.32 | $0.21 | ||
| Q2 25 | $0.33 | $0.14 | ||
| Q1 25 | $0.29 | $-0.77 | ||
| Q4 24 | $0.22 | $0.07 | ||
| Q3 24 | $0.48 | $0.12 | ||
| Q2 24 | $0.48 | $0.08 | ||
| Q1 24 | $0.45 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.7M | $160.2M |
| Total DebtLower is stronger | $468.4M | — |
| Stockholders' EquityBook value | $307.8M | $534.1M |
| Total Assets | $2.2B | $946.5M |
| Debt / EquityLower = less leverage | 1.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.7M | — | ||
| Q3 25 | $11.8M | $160.2M | ||
| Q2 25 | $5.3M | $99.1M | ||
| Q1 25 | $6.5M | $51.7M | ||
| Q4 24 | $10.3M | $95.9M | ||
| Q3 24 | $7.2M | $119.3M | ||
| Q2 24 | $6.9M | $112.5M | ||
| Q1 24 | $7.1M | $132.0M |
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $307.8M | — | ||
| Q3 25 | $316.6M | $534.1M | ||
| Q2 25 | $322.4M | $494.2M | ||
| Q1 25 | $328.4M | $530.9M | ||
| Q4 24 | $335.8M | $596.8M | ||
| Q3 24 | $341.8M | $681.4M | ||
| Q2 24 | $345.7M | $642.8M | ||
| Q1 24 | $347.1M | $618.5M |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $946.5M | ||
| Q2 25 | $2.1B | $918.4M | ||
| Q1 25 | $2.1B | $945.9M | ||
| Q4 24 | $2.1B | $986.3M | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $2.1B | $1.0B | ||
| Q1 24 | $2.0B | $986.6M |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.8M | $33.8M |
| Free Cash FlowOCF − Capex | — | $32.6M |
| FCF MarginFCF / Revenue | — | 34.4% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | 15.35× | 1.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | $80.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.8M | — | ||
| Q3 25 | $20.6M | $33.8M | ||
| Q2 25 | $26.6M | $23.4M | ||
| Q1 25 | $30.4M | $-19.6M | ||
| Q4 24 | $121.2M | $53.0M | ||
| Q3 24 | $26.5M | $19.5M | ||
| Q2 24 | $32.1M | $10.7M | ||
| Q1 24 | $33.8M | $-16.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $32.6M | ||
| Q2 25 | — | $22.0M | ||
| Q1 25 | — | $-23.6M | ||
| Q4 24 | — | $49.5M | ||
| Q3 24 | $-28.3M | $18.1M | ||
| Q2 24 | $-12.5M | $9.9M | ||
| Q1 24 | $-11.7M | $-17.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | 34.4% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | -34.6% | ||
| Q4 24 | — | 68.8% | ||
| Q3 24 | -42.1% | 22.5% | ||
| Q2 24 | -18.7% | 13.5% | ||
| Q1 24 | -17.6% | -34.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | 4.8% | ||
| Q3 24 | 81.5% | 1.7% | ||
| Q2 24 | 66.7% | 1.1% | ||
| Q1 24 | 68.3% | 1.5% |
| Q4 25 | 15.35× | — | ||
| Q3 25 | 1.97× | 1.26× | ||
| Q2 25 | 2.48× | 1.25× | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | 7.52× | ||
| Q3 24 | 1.83× | 1.11× | ||
| Q2 24 | 2.22× | 0.94× | ||
| Q1 24 | 2.48× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFS
Segment breakdown not available.
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
